Rockwell Medical, Inc. · NASDAQ:RMTI
Rockwell Medical — Investor Presentation (January 2024)
18 slides from Rockwell Medical's investor presentation, Jan 9, 2024
Slide 1: Investor Presentation
©) ROCKWELL MEDICAL Investor Presentation January 8, 2024 RMTI Nasdaq |
Slide 2: Forward-Looking Statements and Non-GAAP Measures
Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute "forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell’s expectations regarding revenue, profitability, financial position, 2023 guidan
Slide 3: Rockwell Medical At A Glance
Rockwell Medical At A Glance Business Overview Financial Metrics Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Second largest supplier of acid and bicarbonate concentrates for dialysis patients i
Slide 4: Executive Management Team
Executive Management Team Mark Strobeck, Ph.D. President and CEO Aquilo ASSSERTIO= Tim T. Chole SVP, Sales and Marketing 2 Baxter @GAMBRO. Watson Pharmaceuticals ma RMT Nasdaa Listed Jesse Neri SVP, Finance ARUVANT pa itil © 2024 Rockwell Medical, Inc. ‘Symphony Health Zylam Megan Timmins EVP, Chief
Slide 5: Corporate Strategy
Corporate Strategy Be the Global Leader in Hemodialysis Concentrates Provide Customers with the Highest Quality and Most Reliable Products and Services Achieve Profitability and $100M+ Annual Net Sales Focus on Innovative, Long-Term Growth Opportunities © 2024 Rockwell Medical, Inc. (ROCKWELL MEDICA
Slide 6: What is Hemodialysis?
What is Hemodialysis? * Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. ¢ Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or e
Slide 7: U.S. In-Center Hemodialysis Concentrates Market
U.S. In-Center Hemodialysis Concentrates Market Estimated growth driven primarily by increasing number of patients suffering from end-stage kidney disease TODAY 2026 SOURCE: “Rockwell Medical: Concentrates Growth Strategy Report”, LEK. Consulting LLC (2022) > Ceinerererrsins (ROCKWELL Nasdaq Listed
Slide 8: Indispensable Player in Large, Expanding Market
Indispensable Player in Large, Expanding Market * Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the more than 12,000 individual purchasing facilities (including outpatient dialysis clinics and hospitals) in the U.S., alon
Slide 9: Potential Growth Opportunities and Revenue Streams
Potential Growth Opportunities and Revenue Streams Geographic Expansion Rockwell continues to increase its market share in Western U.S. and internationally Signed Co-Promotion Agreement with B. Braun, targeting customers in the West Acquired hemodialysis concentrates business from Evoqua Water Techn
Slide 10: Acquired Hemodialysis Concentrates Assets from Evoqua
» Acquired Hemodialysis Concentrates Assets from © @VOQUA Background * 20-Year history serving clinics and dialysis patients throughout the U.S. * Legacy brands include Mar Cor, Cantel and Medivators * Well-known throughout the dialysis community Fog RMTI Nasdaq Listed Value Add + Profitable, fully
Slide 11: Rockwell Medical Expands Distribution Footprint in the U.S.
Rockwell Medical Expands Distribution Footprint in the U.S. * Acquired Evoqua’s hemodialysis concentrates customer contracts * Added an additional estimated 1,700 clinics in the U.S. * Rockwell Medical now the leading supplier of liquid bicarbonate products in the U.S. Pre-Acquisition Post-Acquisiti
Slide 12: Financials and Milestones
QROCKWELL Financials and Milestones
Slide 13: Delivering on New Business Strategy
Delivering on New Business Strategy Increasing revenue, reducing expenses, driving the Company towards profitability on an Adjusted EBITDA basis Three Months Ended Twelve Months Ended December 31 December 31 (in Millions, Except Per Share Amounts) Net Sales $ 213 $ 223 $ 19.3 $ 828 § 838 $ 728 Gross
Slide 14: Delivering on New Business Strategy
Delivering on New Business Strategy (sm) (sm) 85 9 82.8- 83.8 ‘ (sm) 20 80 # 6 S AS 75 72.8 & 3 .( 70 2 a0 8.0 1 (2.4) oO 65 5 61.9 & Le = 60 —_— EE. i) 2021 2022 2023 GUIDANCE 2021 2022 2023 GUIDANCE yer YE22 ye23 NOTE: The fourth quarter 2023 and full-year 2023 net sales, gross profit and adjusted
Slide 15: Milestones Achieved in 2023
Milestones Achieved in 2023 ¥ Completed 100% Transfer of Baxter Business with Preferred Economics Expanded Partnerships with Existing Hemodialysis Customers Grew Concentrates Business by Adding New Customers Distributed Hemodialysis Products in New Geographies Completed Integration of Evoqua’s Hemod
Slide 16: Why Invest in Rockwell Medical?
HAPPY 25) LISTING ANNIVERSapy >|)ROCKWEL| thet RMTI NasdaqListed Nasdaq Why Invest in Rockwell Medical? UL) Revenue-Generating Business U) Path to Profitability in Q4’23 U Strengthened Financial Position U) Attractive Valuation © 2024 Rockwell Medical, Inc. LJ Large and Growing Market Opportunity ©R
Slide 17: www.rockwellmed.com IR@rockwellmed.com
www.rockwellmed.com IR@rockwellmed.com
Slide 18: Reconciliation to GAAP Financial Measures
Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat
Rockwell Medical — Investor Presentation (January 2024) on 6ix